Myomo (MYO) Q3 2026 earnings review
Myomo halves its operating loss, but new patient additions drop
Myomo cut its operating loss in half as clinic referrals replaced paid advertising, though cash collections lagged sales. The maker of powered arm braces for paralyzed patients grew third-quarter revenue 22% to $12.3 million, beating its own outlook. Chief executive Paul R. Gudonis lifted the bottom of the full-year revenue plan by $1 million, which by our math points to fourth-quarter growth slowing to 9%.
| Revenue | $12.3M +22% from a year ago |
|---|---|
| Gross margin | 71.3% +7.5 percentage points from a year ago |
| Recurring patient sources share | 54% 33% a year ago |
| Full-year revenue outlook | Narrowed to $46–47M middle of the range: 14% growth |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because lower unit costs and cheaper clinic referrals are offsetting a slower patient funnel, while the gap to positive cash flow remains. MyoConnect therapy locations passed 500 and helped bring Adjusted EBITDA to breakeven, though higher stock-based pay did part of that work. One caution: new patients entering the pipeline fell 19% from last quarter, and third-quarter cash burn used up $1.5 million of the company's $2 million second-half limit.
The question now is whether clinic referrals can lift quarterly sales to the $16 million cash-breakeven mark before loan repayments start next spring. Either the 500-clinic network accelerates orders without extra ad spending, or shrinking pipeline additions cap growth around current levels. Fourth-quarter cash burn and the channel sales breakdown in the quarterly filing will tell.
🐂 Bull Case
Lower Production and Marketing Costs Halved the Operating Loss
"The focus on our four success pillars helped deliver record revenue and solid operating leverage in the quarter, resulting in breakeven Adjusted EBITDA and sequentially lower cash burn", chief executive Paul R. Gudonis said. Myomo makes the MyoPro, a powered arm brace that helps patients with paralysis move their limbs.
Sales rose 22% from a year ago to $12.3 million, while operating expenses grew only 6%. Gross margin expanded by 7.5 percentage points to 71.3% because of higher prices and "the impact of material cost reductions and higher volume, which improved the absorption of fixed costs".
- Cost of making the devices: 28.7% of revenue, down 7.5 percentage points from a year ago
- Selling, clinical and marketing costs: 41.5% of revenue, down 10.6 percentage points
- General and administrative overhead: 29.1% of revenue, down 2.4 percentage points
- Operating loss: $1.7 million, cut in half from $3.5 million a year ago
What to watch: fourth-quarter operating expenses. Management previously said fourth-quarter spending would not exceed the third quarter's $10.5 million, which will show whether the new sales team adds overhead.
Clinic Referrals Now Supply Over Half of Sales
Myomo is shifting away from paid social-media ads and toward recurring patient sources, which include rehabilitation clinics, orthotic and prosthetic partners, and the Department of Veterans Affairs. Gudonis noted that "our MyoConnect program now exceeds 500 referral locations in the U.S., helping to drive revenue from recurring sources".
That network of therapy centers grew from 300 locations last quarter. Recurring channels generated 54% of third-quarter revenue, up from 33% a year ago and 53% in the second quarter. MyoConnect referrals also supplied 18% of all new patients entering the evaluation process this quarter.
This shift matters because therapist referrals carry no advertising cost, allowing the medical robotics maker to cut marketing spending even as sales grow. However, the press release did not break out standalone sales for orthotic partners and international clinics, which live in the quarterly filing.
What to watch: the channel revenue table in the third-quarter 10-Q filing. Rising sales from outside clinics will prove the referral shift is bringing in new business rather than relabeling direct orders.
Insurance Coverage Expands Across States and Health Plans
A patient can only get a MyoPro brace when a government program or private insurer agrees to pay for it, so broader insurance coverage widens Myomo's market. During the third quarter, the company completed Medicaid enrollments in seven states, with more states in progress.
The company is also working on new commercial payer contracts covering an additional 35 million people. Meanwhile, its clinical trial at the University of Utah enrolled 35 of a planned 50 patients, up from 25 last quarter, to gather data supporting private insurance approvals.
What to watch: completion of the 35 million-life payer contracts and full 50-patient enrollment in the Utah study. Signing those insurers will convert pending coverage into billable orders in 2027.
🐻 Bear Case
Stock Pay and Coming Debt Payments Cloud Cash Breakeven
Gudonis highlighted breakeven Adjusted EBITDA, a profit measure that excludes stock-based pay and interest, and said "we continue to expect cash burn to be less than $2 million during the second half of the year". Yet the company still used $1.3 million of cash in operations and saw its total cash drop by $1.5 million to $11.9 million.
Adjusted EBITDA reached breakeven in part because Myomo paid more compensation in shares: stock-based pay more than doubled from a year ago to $1.3 million. Meanwhile, the portion of long-term debt due within 12 months rose to $1.8 million from $0.4 million in June as loan repayments approach in 2027.
Because third-quarter cash burn took up $1.5 million of the second-half limit, by our math Myomo can burn at most $0.5 million in the fourth quarter to meet its plan. Quarterly sales of $12.3 million also remain below the $16 million to $17 million level management has said it needs to stop burning cash.
What to watch: fourth-quarter cash change against the $0.5 million remaining room. Burning more than that will test liquidity just as monthly loan principal payments begin next spring.
New Patient Additions Dropped as Order Growth Slowed
Before Myomo can record an order or deliver a brace, it must bring patients into its reimbursement pipeline to seek insurance approval. While third-quarter orders hit a record 258, the flow of new patients entering the top of that funnel shrank.
- New pipeline additions: 600 patients, down 19% from last quarter and down 27% from a year ago by our math
- Total orders: 258, up 13% from a year ago, slowing from 23% growth in the second quarter
- Sequential order growth: up 1% from 255 in the second quarter by our math
The press release did not report total patients in the pipeline, ending unit backlog, or acquisition cost per patient. Because fewer candidates entered the funnel in the third quarter, keeping deliveries growing will require a higher share of candidates to win insurance approval.
What to watch: total patient backlog and pipeline counts in the quarterly filing or conference call. A third straight drop in backlog would show that deliveries are draining stored demand.
Risks this quarter didn't answer
Five standing business risks received no updated figures in the third-quarter earnings release.
- Medicare Part B concentration: not in the release; the 10-Q filing will show whether government fee-schedule patients still represent roughly half of sales.
- Medicare Advantage denials: the Utah trial is still enrolling and will not publish results until 2027, leaving private Medicare approval rates untested.
- Monthly loan covenants: the internal revenue budget that triggers the Avenue Capital loan covenant remains undisclosed.
- International and single-product concentration: the Germany revenue split awaits the 10-Q, while the MyoPro3 and German hand-only brace remain in development.
- Channel price dilution: average selling price held at $55,500 this quarter, but the 10-Q channel mix will show whether lower-priced clinic sales are pressuring unit pricing.
👓 Other Themes
Former Inspire Medical Executive Hired to Run Sales
Myomo hired Mary-Katherine McClure as Chief Commercial Officer in October to lead its shift toward recurring clinic referrals. McClure previously worked as a sales executive at Inspire Medical, where she grew territory sales from $2 million to $150 million, and she will start by "organizing and building the Company’s commercial operations team to drive additional revenue growth".
💲 Other KPIs
Uncollected customer bills rose faster than sales. Accounts receivable climbed 19.7% from last quarter and 44.6% from the end of 2025 by our math, while quarterly revenue grew 5.3% sequentially. That $1.7 million nine-month build in unpaid bills tied up cash and accounted for nearly a third of the company's operating cash burn this year.
Unit volume carried the top-line increase. Myomo recorded revenue on 222 arm braces, up 19% from 186 a year ago and up from 211 in the second quarter. The average selling price rose 2% from a year ago to roughly $55,500, matching last quarter's price despite the growing share of wholesale orthotic clinic orders.
The bottom-line loss widened even as operating losses shrank. Net loss rose 15.6% from a year ago because the robotics group recorded a $1.85 million non-cash accounting charge for the changing value of warrant liabilities and $0.56 million in net interest costs. Weighted average shares rose 3.3% from a year ago to 43.6 million.
🔮 Guidance
Raised. Management lifted the bottom of the full-year range by $1 million, pushing the middle of the range up $0.5 million to 13.6% annual growth. By our math, that leaves $11.9 million to $12.9 million for the fourth quarter, or 8.8% growth at the middle of the range, down from 22.2% in Q3. Myomo has beaten its quarterly midpoint by an average of 6.6% over the last five guided quarters; if the pattern holds, Q4 revenue would reach $13.2 million.
Unchanged. The US device maker still plans to burn less than $2 million of cash across the second half of 2026, down from $4.1 million of operating cash used in the first half. Because cash and investments fell by $1.5 million in the third quarter, by our math the plan leaves less than $0.5 million of room for fourth-quarter cash burn.
Unchanged. Gudonis reiterated the full-year operating leverage target. Through the first nine months of 2026, revenue rose 15% from a year ago while operating expenses grew less than 2% by our math, keeping the company well inside its full-year expense cap.
❓ Key Questions
Why did new pipeline additions fall to 600 patients?
Patients added to the pipeline dropped 19% from the second quarter and 27% from a year ago. Investors need to know whether lower ad spending caused the drop and what total backlog and acquisition cost per patient looked like at quarter-end.
Will Myomo collect receivables fast enough to meet its cash target?
Third-quarter cash burn of $1.5 million leaves less than $0.5 million of room under the $2 million second-half cap. With accounts receivable up almost $1 million in Q3, fourth-quarter cash flow depends on collecting unpaid insurance bills.
What did standalone provider and international channels earn in Q3?
The release grouped clinic referrals, orthotic partners, and Veterans Affairs sales into a single 54% recurring share. Breaking out third-party provider revenue against direct billing will show whether outside clinics are expanding total demand.
How will the new commercial chief change sales spending in 2027?
Katie McClure joined in October to build out the commercial operations team, while loan principal payments start in May 2027. Management has not said whether hiring for her team will raise the $16–17 million quarterly revenue level needed to break even.